Brokerages predict that Boston Scientific Corporation (NYSE:BSX) will report sales of $2.34 billion for the current quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Boston Scientific’s earnings, with the lowest sales estimate coming in at $2.32 billion and the highest estimate coming in at $2.36 billion. Boston Scientific reported sales of $2.16 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.3%. The business is scheduled to issue its next earnings report on Thursday, April 26th.

According to Zacks, analysts expect that Boston Scientific will report full year sales of $2.34 billion for the current fiscal year, with estimates ranging from $9.70 billion to $9.77 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $10.32 billion per share, with estimates ranging from $9.90 billion to $10.54 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Boston Scientific.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same quarter in the prior year, the business posted $0.30 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year.

Several research analysts recently weighed in on the company. Jefferies Group reaffirmed a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd. TheStreet raised Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. Barclays reaffirmed a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research note on Wednesday, January 10th. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. Finally, BMO Capital Markets raised their target price on Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $31.00.

In other Boston Scientific news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of Boston Scientific stock in a transaction that occurred on Tuesday, November 28th. The stock was purchased at an average cost of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 5,152 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the sale, the senior vice president now directly owns 38,116 shares of the company’s stock, valued at $1,029,132. The disclosure for this sale can be found here. Over the last three months, insiders sold 161,464 shares of company stock valued at $4,253,617. Company insiders own 0.74% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Sit Investment Associates Inc. lifted its stake in Boston Scientific by 37.8% in the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after acquiring an additional 38,855 shares in the last quarter. Greenwood Capital Associates LLC increased its position in Boston Scientific by 71.7% in the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after purchasing an additional 38,249 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its position in Boston Scientific by 94.9% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock worth $1,126,000 after purchasing an additional 18,800 shares during the last quarter. LS Investment Advisors LLC increased its position in Boston Scientific by 5.8% in the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after purchasing an additional 2,209 shares during the last quarter. Finally, Chevy Chase Trust Holdings Inc. increased its position in Boston Scientific by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock worth $34,934,000 after purchasing an additional 16,992 shares during the last quarter. 90.15% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific (NYSE BSX) opened at $25.92 on Monday. Boston Scientific has a 52 week low of $23.29 and a 52 week high of $29.93. The stock has a market capitalization of $35,590.00, a price-to-earnings ratio of 370.29, a PEG ratio of 1.88 and a beta of 0.81. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/02/12/boston-scientific-corporation-bsx-expected-to-post-quarterly-sales-of-2-34-billion.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.